Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Affymax logo — Pioneering innovative therapies for life-threatening conditi...

Affymax

Pioneering innovative therapies for life-threatening conditions, aiming to enhance anemia treatment in chronic kidney disease patients.

Founded 2001 51-200 employees Series Unknown Total: $173.00M Biopharma, Biotechnology +1

General Information

Company Name Affymax
Founded Year 2001
Founders / Decision Makers
Team member
Employees 51-200
Industries Biopharma, Biotechnology, Health Care
Funding Stage Series Unknown
Social

Get notified when Affymax moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Affymax

Affymax is a biopharmaceutical company founded in 2001 with a focus on pioneering innovative therapies for life-threatening conditions. Their flagship product candidate, peginesatide (previously known as Hematide™), has completed Phase 3 trials for treating anemia in chronic kidney disease (CKD) patients. The company has recently received a $42.00M Venture Round investment on March 3, 2009 from investors Bessemer Venture Partners, Sprout Group, ProQuest. Affymax's ambition to enhance anemia treatment for CKD patients underlines its positioning in the Biopharma, Biotechnology, and Health Care industries. The company's current focus is on obtaining approval from the U.S. Food and Drug Administration (FDA) for peginesatide to address anemia in adult CKD patients on dialysis.

Taxonomy: biopharmaceutical company, drug development, innovative therapies, anemia treatment, chronic kidney disease, peginesatide, Phase 3 trials, FDA review, New Drug Application, life-threatening conditions, dialysis patients

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 3
Investor Investor
•••• •••• 		03 Mar 2009
Series D •••••• 7
Investor Investor Investor Investor Investor Investor Investor
18 Jul 2005
Series C •••••• - 14 Apr 2004
Private Equity Round •••••• - 30 Jul 2001

Affymax Alternatives & Competitors

Affymax vs
Fe3 Medical, Inc.
Fe3 Medical, Inc. United States

Revolutionizing iron-deficiency anemia treatment with a safe, non-toxic transdermal drug delivery te...

Series B
1 employees
Biotechnology, Health Care
Affymax vs
Tricida, Inc.
Tricida, Inc. United States

Tricida is a pharmaceutical company working to turn the tide on metabolic acidosis and progression o...

Post Ipo Debt
16 employees
Health Care, Pharmaceutical
Affymax vs
DOSIS
DOSIS United States

AI-powered personalized dosing platform

6 employees
AI, Health Care

FAQ About Affymax

Pioneering innovative therapies for life-threatening conditions, aiming to enhance anemia treatment in chronic kidney disease patients.
Affymax was founded in 2001.
Affymax operates in the following industries: Biopharma, Biotechnology, Health Care.
Affymax has approximately 51-200 employees.
Affymax has completed 4 funding rounds, raising a total of $173.00M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Affymax include Fe3 Medical, Inc., Tricida, Inc., DOSIS, Rege Nephro Co., Ltd., Scout Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Affymax and Fe3 Medical, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Affymax and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy